Voydeya approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of EVH in adults with PNH
Voydeya (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is a first-in-class, oral, Factor D inhibitor developed as an…